人民财讯9月17日电，长春高新（000661）9月17日晚间公告，控股子公司金赛药业与丹麦ALK- AbellóA/S公司达成变应原特异性免疫治疗(AIT)产品合作，将在中国联合开发并商业化ALK的屋尘螨 (HDM)变应原特异性免疫治疗产品，并获得ALK自主开发的3款产品在中国大陆范围内的独家代理权 益。根据协议，金赛药业将支付首付款3270万欧元，针对尘螨变应原舌下片(ACARIZAX)成人、青少年 及儿童适应症在中国区域内药品监管部门的临床试验监管审批进展，金赛药业将后续支付注册里程碑付 款4000万欧元。未来，根据上述产品在中国市场的销售情况，金赛药业或后续支付销售里程碑1.05亿欧 元。 ...

Core Viewpoint - Changchun High-tech announced a collaboration with Danish company ALK-Abelló A/S to develop and commercialize allergen-specific immunotherapy (AIT) products for house dust mites (HDM) in China, gaining exclusive rights to three of ALK's independently developed products in mainland China [1] Group 1 - Changchun High-tech's subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., will work with ALK on the AIT products [1] - The collaboration focuses on the development and commercialization of HDM allergen-specific immunotherapy products in the Chinese market [1] - The agreement includes exclusive agency rights for three ALK-developed products within mainland China [1]

根据双方合作协议约定，金赛药业将获得ALK的3款产品在中国大陆地区的独家权益，包括皮下注射用 屋尘螨变应原制剂(安脱达)、螨变应原皮肤点刺试剂盒(安刺)及尘螨变应原舌下片(ACARIZAX®)，合作 权益期限至2039年12月31日止。金赛药业将支付首付款3,270万欧元，获得上述3款产品在中国大陆地区 的商业化权益。 智通财经APP讯，长春高新(000661.SZ)公告，公司控股子公司——长春金赛药业有限责任公司(简称"金 赛药业")与丹麦ALK-AbellóA/S公司(简称"ALK")达成变应原特异性免疫治疗(AIT)产品合作，将在中国 联合开发并商业化ALK的屋尘螨(HDM)变应原特异性免疫治疗产品，并获得ALK自主开发的3款产品在 中国大陆范围内的独家代理权益。 ...

Group 1 - The core point of the article is that Changchun High-tech (SZ 000661) announced a collaboration with Danish company ALK-Abelló A/S for allergen-specific immunotherapy (AIT) products during its board meeting on September 17, 2025 [1] - For the first half of 2025, the revenue composition of Changchun High-tech was as follows: 92.83% from the pharmaceutical industry, 6.81% from real estate, and 0.36% from services [1] - As of the report date, the market capitalization of Changchun High-tech was 50.5 billion yuan [1]

证券代码：000661 证券简称：长春高新 公告编号：2025-128 长春高新技术产业（集团）股份有限公司 关于子公司与丹麦 ALK-Abelló A/S 公司 达成变应原特异性免疫治疗（AIT）产品合作的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 长春高新技术产业（集团）股份有限公司（以下简称"公司"）控股子公司 ——长春金赛药业有限责任公司（以下简称"金赛药业"）与丹麦 ALK-Abelló A/S 公司（以下简称"ALK"）达成变应原特异性免疫治疗（AIT）产品合作，将在中 国联合开发并商业化 ALK 的屋尘螨（HDM）变应原特异性免疫治疗产品，并获得 ALK 自主开发的 3 款产品在中国大陆（以下简称"合作地域"）范围内的独家代 理权益。 一、许可产品基本信息 本次合作产品为 ALK 自主开发的 3 款产品，包括 2 款变应原特异性免疫治疗 产品和 1 款用于螨变应原检测的皮肤点刺试剂盒： ①屋尘螨变应原制剂（安脱达）：一款在中国已上市销售的皮下注射免疫治 疗屋尘螨变应原制剂； ②尘螨变应原舌下片（ACARIZAX®）：为全球首款被批准用于 ...

证券代码：000661 证券简称：长春高新 公告编号：2025-127 长春高新技术产业（集团）股份有限公司 第十一届董事会第十三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、经长春高新技术产业（集团）股份有限公司（以下简称"公司"）半数 以上董事同意，公司第十一届董事会第十三次会议于 2025 年 9 月 13 日以微信方 式发出会议通知。 2、本次董事会于 2025 年 9 月 17 日 14 时以现场结合通讯方式召开。 3、本次会议应参与表决董事 9 名，实际参与表决董事 9 名。 4、会议由董事长姜云涛先生主持，公司高级管理人员列席了本次会议。 经与会董事认真讨论，本次会议审议通过了《关于子公司与丹麦 ALK-Abelló A/S 公司达成变应原特异性免疫治疗（AIT）产品合作的议案》。 表决结果：9 票同意，0 票反对，0 票弃权。 子公司长春金赛药业有限责任公司与丹麦 ALK-Abelló A/S 公司（以下简称 "ALK"）达成变应原特异性免疫治疗（AIT）产品合作，将在中国联合开发并商 业化 ALK ...

Core Viewpoint - Changchun High-tech announced a collaboration between its subsidiary Jinsai Pharmaceutical and Denmark's ALK-Abelló A/S for the development and commercialization of allergen-specific immunotherapy (AIT) products in China, specifically targeting house dust mites (HDM) [1] Group 1: Partnership Details - Jinsai Pharmaceutical will jointly develop and commercialize ALK's HDM allergen-specific immunotherapy products in China [1] - Jinsai Pharmaceutical has secured exclusive agency rights for three products independently developed by ALK within mainland China [1] Group 2: Financial Terms - An initial payment of €32.7 million will be made by Jinsai Pharmaceutical [1] - Jinsai Pharmaceutical will pay a milestone payment of €40 million upon regulatory approval for clinical trials of the ACARIZAX sublingual tablet for adults, adolescents, and children in China [1] - Future sales performance of the products in the Chinese market may lead to additional milestone payments of €105 million [1]

Group 1 - The Biotech Index (970038) closed at 2403.29 points, down 0.55%, with a trading volume of 25.269 billion yuan and a turnover rate of 1.59% [1] - Among the index constituents, 11 stocks rose, led by Jingxin Pharmaceutical with a 2.67% increase, while 38 stocks fell, with Yaoshi Technology leading the decline at 5.11% [1] - The top ten constituents of the Biotech Index include major companies such as Mindray Medical, with a weight of 13.82% and a market cap of 290.246 billion yuan, and other notable firms like Tigermed and Changchun High-tech [1] Group 2 - The net outflow of main funds from the Biotech Index constituents totaled 1.789 billion yuan, while retail investors saw a net inflow of 1.354 billion yuan [3] - Specific stocks like Boteng Co. experienced a net inflow of 73.5819 million yuan from main funds, while others like Jiayin Pharmaceutical saw a net outflow of 4.8669 million yuan [3] - The overall trend indicates a mixed sentiment among institutional and retail investors, with significant movements in individual stocks reflecting varying levels of confidence [3]

Group 1 - The company appointed Xie Bing as the new Vice General Manager, effective until the end of the 11th Board of Directors term [1][2] - Xie Bing has a background in finance and management, previously serving as the head of the Finance Bureau and State-owned Assets Supervision and Administration Commission in Changchun New Area [2] - The appointment comes at a time when the company is facing significant pressure on its performance, with total revenue for the first half of 2025 at 6.60 billion yuan, a slight decrease of 0.54% year-on-year, and a net profit of 982.87 million yuan, down 42.85% [2][3] Group 2 - Despite the financial challenges, the company's stock price has shown resilience, closing at 123.85 yuan per share on September 16, 2025, with a year-to-date increase of 27.55% [2] - The total market capitalization reached 50.52 billion yuan, indicating sustained investor interest [2] - The company reported a significant decline in profit margins, with basic earnings per share dropping to 2.44 yuan, a decrease of 42.99% compared to the previous year [3]

Group 1 - The core viewpoint of the news is that Changchun High-tech has experienced fluctuations in stock price and trading volume, with a recent decline of 2.01% on September 16, 2023, and a total market capitalization of 50.69 billion yuan [1] - As of June 30, 2023, Changchun High-tech's revenue for the first half of 2023 was 6.603 billion yuan, a year-on-year decrease of 0.54%, while the net profit attributable to shareholders was 983 million yuan, down 42.85% year-on-year [2] - The company has a strong focus on the pharmaceutical industry, with 92.83% of its revenue coming from pharmaceuticals, while real estate and service sectors contribute 6.81% and 0.36% respectively [1][2] Group 2 - Changchun High-tech has a history of dividend payments, with a total of 4.791 billion yuan distributed since its A-share listing, and 3.259 billion yuan in the last three years [3] - The company is categorized under the pharmaceutical and biological industry, specifically in the sub-sector of biological products, and is associated with concepts such as Northeast revitalization and innovative drugs [2] - As of June 30, 2023, the number of shareholders decreased by 12.78% to 109,100, while the average circulating shares per person increased by 14.66% to 3,662 shares [2]